Vaccine makers field takeover bids

摘要

Hoping to get a head start on the flu and cold season,GlaxoSmithKline officials said they will pay US 1.4 billion to acquire ID Biomedkal,a Canadian vaccine maker.Just the week before the Glaxo deal,Novartis offered M.5 billion for the remaining 58% of Emeryville,Cahf,based flu shot maker Chiron it does not already own.So fat;Chiron is fighting off that offer,saying it is too low.